First-In-Human Trials of GamTBvac, a Recombinant Subunit Tuberculosis Vaccine Candidate: Safety and Immunogenicity Assessment

Tuberculosis is known to be the biggest global health problem, causing the most deaths by a single infectious agent. Vaccine-development efforts are extremely important. This paper represents the results of the first-in-human trial of recombinant subunit tuberculosis vaccine GamTBvac in a Phase I st...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Daria V. Vasina, Denis A. Kleymenov, Victor A. Manuylov, Elena P. Mazunina, Egor Yu. Koptev, Elena A. Tukhovskaya, Arkady N. Murashev, Alexander L. Gintsburg, Vladimir A. Gushchin, Artem P. Tkachuk
Formato: Artigo
Idioma:Inglês
Publicado em: MDPI AG 2019-11-01
Colecção:Vaccines
Assuntos:
tuberculosis
subunit vaccine
bcg booster
clinical trials
safety and immunogenicity
Acesso em linha:https://www.mdpi.com/2076-393X/7/4/166
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados